Skip to main content
OpenTrials
Completed

NCT Number: NCT04252716

VISPER: Randomised Comparison of Two OVDs in Cataract Surgery

To investigate that VISTHESIA 1.5 is non-inferior to Provisc with regards to elevation in IOP greater than or equal to 30 mm Hg 6 ± 2 hours post-operatively as per methodology set out in EN ISO 15798:2013 (Primary Endpoint) To compare the changes in endothelial cell count and incidences of intraocular inflammation between VISTHESIA and Provisc as per methodology set out in EN ISO 15798:2013

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

50 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University hospital Freiburg

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients of any gender, 50 years of age or older at the time of study enrolment
  • undergoing age-related cataract removal (phacoemulsification) and IOL implantation in one eye only
  • Patient informed of the needs and visit schedule required of the Clinical Investigational Plan and who has given his/her written informed consent
  • Planned implantation of the IOL in the capsular bag

Exclusion criteria

  • Patients not able to / willing to give informed consent
  • Patients not able to comprehend and comply with study requirements
  • Patients scheduled for surgery to the fellow eye within 48 hrs preceding any scheduled study follow up. (Surgery date could be changed)
  • Patients not able to attend follow-up appointments for any reason
  • Patients with known hypersensitivity to anaesthetics of the amide type or hyaluronan
  • Patients with reduced corneal endothelium (e.g. Fuch's dystrophy)
  • Patients with epilepsy, impaired cardiac conduction, bradycardia, or impaired respiratory function
  • Patients being treated with tocainide for cardiac arrhythmia
  • Patients with impaired hepatic function, if the anaesthetic dose or site of application is likely to result in high blood levels
  • Mono-ophthalmic patients
  • Patients who have previously undergone cataract surgery in the contralateral eye
  • Patients with any psychosocial, or other chronic disease conditions that may affect the perception of bodily pain
  • VISTHESIA (topical and intracameral components) or ProVisc is not a suitable device for the patient for any reason
  • Patients with other pathology or condition presenting, according to the investigator opinion, a risk for the patient (to be documented in screen log)
  • Female patients who are menstruating, pregnant, breastfeeding or amenorrheic for less than 2 years at the time of surgery
  • Patients who may require the use of hyaluronidase as part of the study cataract procedure
  • Patients who may be regarded as being vulnerable (e.g. prisoners, residents of care or mental health institutions, trauma, war or disaster victims, dependent on the investigator etc.)

Treatment and study plan

OVD

Device

Intraocular administration

Primary outcomes

  1. IOP

    Time frame: 6-hours post-operatively

    Frequency of incidence of Intraocular Pressure greater than or equal to 30 mm Hg

Sponsors and collaborators

Lead sponsor

Carl Zeiss Meditec AG

Industry

Registry information

Official study title

Prospective, Randomized, Multi-centre, Observer-masked, Non-inferiority Comparison of Two Cohesive Viscoelastic Solutions: VISTHESIA v Provisc

Acronym: VISPER

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
Feb 5, 2020
Registry last updated
Mar 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.